Each story puts the development into perspective, so you can see how it affects your goals, your market or your next move.
Journalism shaped by years of experience in medtech, with direct access to company executives, medical KOLs, investors, regulators and analysts.
Analysis that goes beyond the news to help medtech leaders interpret what is happening and plan what to do about it.
Every story frames the development in strategic context, so readers see the consequences for their market and their programs.
Medtech Insight’s reporters have the access that produces reporting other sources cannot match.
Trackers – M&A, financings, approvals, global guidance, FDA warning letters, Breakthrough Devices
FDA, EU MDR and IVDR, and global regulatory change, with the compliance consequences explained.
Software as a medical device, AI clearances, wearables and the rules being written around them.
Coverage decisions, coding and payment policy across the major device markets.
M&A, financings, alliances and the strategic reasoning behind them.
Cardiology, orthopedics, neurotech, diagnostic imaging, IVD and surgical technologies.
Regulatory teams use Medtech Insight’s coverage of FDA activity, EU MDR and IVDR developments and global guidance to see where requirements are moving, so submission and compliance planning starts from a current picture rather than a published rulebook.
Regulatory leaders track FDA activity, MDR and IVDR developments and global guidance to plan submissions and manage compliance risk.
Finance and corp dev teams follow the MTI 100, M&A activity and financing trends to inform valuation and transaction decisions.
Product teams monitor competitor clearances, clinical evidence requirements and the technologies gaining traction in their device areas.
Commercial and access teams follow reimbursement decisions, coding changes and procurement policy across key markets.
Lawyers and consultants serving the device industry use Medtech Insight as a primary source in advisory and diligence work.
Investors and medtech founders track trends, obstacles and deal activity when evaluating or building companies in the sector.
Norstella’s award-winning publications provide in-depth coverage of the life sciences industry, thanks to 60+ in-house journalists who tackle the tough issues with precision, persistence and passion.
Real-time analysis, news and opinion across the medtech sector, covering regulatory, product and company developments.
